---
title: "LIXT.US (LIXT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LIXT.US/news.md"
symbol: "LIXT.US"
name: "LIXT.US"
parent: "https://longbridge.com/en/quote/LIXT.US.md"
datetime: "2026-05-21T21:41:24.958Z"
locales:
  - [en](https://longbridge.com/en/quote/LIXT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LIXT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LIXT.US/news.md)
---

# LIXT.US (LIXT.US) — Related News

### [LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update | LIXT Stock News](https://longbridge.com/en/news/286470542.md)
*2026-05-14T13:20:37.000Z*
> LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update | LIXT 

### [Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan](https://longbridge.com/en/news/282239732.md)
*2026-04-09T19:02:23.000Z*
> Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan

### [Lixte Biotechnology | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/281232123.md)
*2026-03-31T19:15:44.000Z*
### [Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS](https://longbridge.com/en/news/281232249.md)
*2026-03-31T19:15:02.000Z*
> Lixte Biotechnology Holdings reported no revenue for 2025, with a net loss of $6.01 million and a loss per share of $(1.

### [LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year | LIXT Stock News](https://longbridge.com/en/news/281233760.md)
*2026-03-31T11:45:39.000Z*
> LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year | LIXT 

### [Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend](https://longbridge.com/en/news/280438130.md)
*2026-03-25T08:33:35.000Z*
> Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend

### [Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise](https://longbridge.com/en/news/280270239.md)
*2026-03-24T07:02:40.000Z*
> Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise